StoneX Group Inc. Has $1.28 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

StoneX Group Inc. trimmed its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 28.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,467 shares of the pharmacy operator's stock after selling 11,105 shares during the quarter. StoneX Group Inc.'s holdings in CVS Health were worth $1,278,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in CVS. State Street Corp lifted its stake in CVS Health by 3.6% during the third quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator's stock worth $3,554,475,000 after purchasing an additional 1,989,066 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of CVS Health by 1.8% during the third quarter. Geode Capital Management LLC now owns 26,361,673 shares of the pharmacy operator's stock worth $1,651,997,000 after purchasing an additional 461,569 shares during the period. Pzena Investment Management LLC lifted its position in shares of CVS Health by 49.3% in the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after buying an additional 6,475,271 shares during the last quarter. Norges Bank acquired a new position in shares of CVS Health in the 4th quarter valued at about $839,574,000. Finally, Charles Schwab Investment Management Inc. raised its stake in CVS Health by 5.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 12,918,949 shares of the pharmacy operator's stock worth $579,932,000 after acquiring an additional 710,281 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Remove Ads

CVS Health Price Performance

NYSE CVS traded down $3.97 on Friday, reaching $63.54. The company's stock had a trading volume of 13,291,234 shares, compared to its average volume of 11,586,970. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $74.85. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm's 50 day moving average is $63.47 and its two-hundred day moving average is $58.01. The stock has a market cap of $80.11 billion, a PE ratio of 17.36, a PEG ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, sell-side analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.19%. The ex-dividend date is Tuesday, April 22nd. CVS Health's dividend payout ratio is 72.68%.

Insider Activity at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CVS has been the subject of several recent research reports. Cantor Fitzgerald raised CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a research report on Friday, March 21st. Evercore ISI boosted their price target on shares of CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a report on Monday, January 27th. Edward Jones raised shares of CVS Health from a "hold" rating to a "buy" rating in a report on Thursday, January 30th. Finally, Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.39.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.